|1.||German-Fattal, Michèle: 2 articles (11/2004 - 01/2003)|
|2.||Jurkiewicz, Dariusz: 2 articles (04/2004 - 03/2003)|
|3.||De Spiegeleer, Bart: 1 article (08/2015)|
|4.||Taevernier, Lien: 1 article (08/2015)|
|5.||Veryser, Lieselotte: 1 article (08/2015)|
|6.||Detroyer, Sven: 1 article (08/2015)|
|7.||Pearce, Cedric J: 1 article (11/2012)|
|8.||Sy-Cordero, Arlene A: 1 article (11/2012)|
|9.||Oberlies, Nicholas H: 1 article (11/2012)|
|10.||Shmelev, E I: 1 article (01/2008)|
01/01/1998 - "AR is a good instrument to be used in the objective assessment of the nasal blockade changes in people with infection of the nasal mucosa and showed positive efficacy of fusafungine in the treatment of upper airway infection."
01/01/1991 - "This effect of fusafungine should prevent but not eradicate colonization of the nasopharyngeal mucosa by Haemophilus influenzae and may account for the therapeutic efficacy reported in infections of the respiratory tract due to Haemophilus influenzae."
01/01/2002 - "Results of this study suggest that fusafungine, whatever the aetiology of the infection, gives rapid relief of nasal and pharyngeal symptoms and provides strong evidence of its efficacy and acceptability in treating URTIs."
01/01/1998 - "The aim of the study was to estimate by means of acoustic rhinometry (AR) the nasal blockade in 37 patients (5-73 years old, mean 32) with upper airways infections treated by fusafungine. "
01/01/1991 - "Adherence to human epithelial cells in continuous lines, HeLa and Hep2, of 8 piliated strains of Haemophilus influenzae isolated from human infections of the respiratory tract was studied in vitro in the presence of fusafungine, a local bacteriostatic antibiotic. "
|2.||Pharyngitis (Sore Throat)
01/01/2002 - "Therapeutic efficacy and clinical acceptability of fusafungine in follicular pharyngitis."
01/01/2002 - "Results confirmed the efficacy of fusafungine in the treatment of local and symptomatic manifestations of follicular pharyngitis. "
01/01/2002 - "Eighty-one patients suffering from follicular pharyngitis were treated for 7 days in a double-blind, multicentre controlled study of fusafungine versus placebo. "
01/01/2002 - "Effects of follicular pharyngitis on day-to-day life decreased after 7 days of treatment and the differences between the treatment group and the placebo group was close to significance in favour of fusafungine. "
04/01/2004 - "Post-tonsillectomy fusafungine use was found to improve the patients' quality of life, appeases the sore throat and swallowing difficulties, decreases the need for general antibiotic therapy; the above results are statistically significant. "
02/01/1994 - "An analysis of subgroups (ineffectively treated patients and patients with long-lasting symptoms and complaints) shows that fusafungin was effective therapeutically for treating for acute laryngitis. "
02/01/1994 - "[Therapy of isolated acute laryngitis with fusafungin. "
02/01/1994 - "Four-hundred and eighty-four patients with acute laryngitis were examined before and after treatment with fusafungin under phase IV conditions. "
01/01/2015 - "However, no significant differences were found at days 8 ± 1 and 28 ± 2. Also, no significant differences were found when comparing fusafungine to fusafungine plus clarithromycin at days 5 ± 1, 8 ± 1 and 28 ± 2. Antibiotics do not appear to be effective in treating acute laryngitis when assessing objective outcomes. "
01/01/1999 - "The principal indications of Bioparox Spray for treatment of respiratory tract infections fall within the range from the sinuses to the finest alveolar duct, namely: rhinitis, sinusitis, tonsillitis, pharyngitis, laryngitis, tracheitis and bronchitis. "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
03/01/2003 - "The aim of the study was evaluation of efficacy and safety of new form of fusafungine in the treatment of upper respiratory tract infections in adults. "
01/01/2002 - "This open, multi-centre study analysed data on 166 patients suffering from upper respiratory tract infections treated for 7 or 10 days with a fusafungine metered-dose spray. "
01/01/2002 - "The objective of this study was to assess the effectiveness and acceptability of fusafungine in the treatment of patients with community-acquired, upper respiratory tract infections. "
12/01/2004 - "Besides its bacteriostatic activity against most micro-organisms involved in respiratory tract infections fusafungine displays original anti-inflammatory properties. "
11/01/2004 - "How to improve current therapeutic standards in upper respiratory infections: value of fusafungine."
08/01/2004 - "Fusafungine administration after tonsillectomy was found to be beneficial on post-operative pain and wound healing of tonsillary beds in pediatric population."
08/01/2004 - "To investigate the effect of fusafungine spray on pain and healing process after pediatric tonsillectomy. "
08/01/2004 - "The effect of fusafungine on post-operative pain and wound healing after pediatric tonsillectomy."
06/01/2002 - "The aim of the study was to estimate whether fusafungine in spray has an effect on healing process after the operation, especially on pain and consumption of analgesics. "
06/01/2002 - "Fusafungine in spray significantly reduces pain in the early days (2 - 4 day) after the operation and offers almost 16 % decrease in total consumption of analgesics (p < 0.04). "
|1.||Anti-Bacterial Agents (Antibiotics)
|3.||Analgesics (Analgesic Drugs)
|6.||Methane Chlorofluorocarbons (Freon)